Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$1.69M Buy
94,526
+2,500
+3% +$36.3K 0.66% 42
2025
Q2
$998K Buy
92,026
+10,725
+13% +$141K 0.4% 47
2025
Q1
$1.5M Buy
81,301
+801
+1% +$14.5K 0.63% 41
2024
Q4
$1.33M Buy
80,500
+7,000
+10% +$99.1K 0.52% 46
2024
Q3
$1.03M Buy
73,500
+50,500
+220% +$559K 0.38% 47
2024
Q2
$167K Sell
23,000
-2,500
-10% -$17.1K 0.07% 65
2024
Q1
$206K Buy
25,500
+3,000
+13% +$26.9K 0.08% 65
2023
Q4
$154K Buy
+22,500
New +$125K 0.07% 65

Other funds holding AXGN

Stone Run Capital's AXGN Position: Q3 2025 in Review

Stone Run Capital increased its Axogen (AXGN) stake by 2.7% in Q3 2025, buying an estimated $36.3K and bringing the position to 94,526 shares worth $1.69M. The position accounts for 0.66% of the portfolio, ranked #42.

Stone Run Capital first reported a position in AXGN in Q4 2023 and has held it in 8 quarters since. 171 funds tracked by Wall St. Rank hold AXGN as of Q3 2025.

  • Stone Run Capital held 94,526 shares of Axogen worth $1.69M as of Q3 2025.
  • Stone Run Capital bought 2,500 Axogen shares in Q3 2025, an estimated $36.3K.
  • Axogen made up 0.66% of Stone Run Capital's portfolio in Q3 2025, its #42 holding.
  • Stone Run Capital first reported a position in Axogen in Q4 2023 and has held it in 8 quarters since.
  • 171 funds tracked by Wall St. Rank held Axogen as of Q3 2025.

Based on Stone Run Capital's 13F filing for Q3 2025, filed 14 Nov 2025.